Press Releases
Samsung Biologics showcases CDO capabilities at BPI 2023
Samsung Biologics showcased its latest capacity expansion and CDO capabilities at BioProcess International 2023 held in Boston between September 18-21.
The company shared the latest developments regarding Bio Campus II and promoted its CDO services, including proprietary platforms and new customized CMC solutions for optimized drug development.
Samsung Biologics also participated in poster sessions as well as a speaking session where Janet Lee, Director of Cell Line Development, shared her insights on how utilizing the company's S-CHOice® CLD platform can maximize protein efficiency.
To learn more about Samsung Biologics' CDO services, visit the CDO page or download the brochure for more information.
Samsung Biologics showcased its latest capacity expansion and CDO capabilities at BioProcess International 2023 held in Boston between September 18-21.
The company shared the latest developments regarding Bio Campus II and promoted its CDO services, including proprietary platforms and new customized CMC solutions for optimized drug development.
Samsung Biologics also participated in poster sessions as well as a speaking session where Janet Lee, Director of Cell Line Development, shared her insights on how utilizing the company's S-CHOice® CLD platform can maximize protein efficiency.
To learn more about Samsung Biologics' CDO services, visit the CDO page or download the brochure for more information.